In­tro­duc­ing End­points FDA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

CRLs. 483s. CBER, CDER and RWE. For bio­phar­ma pro­fes­sion­als, these acronyms com­mand at­ten­tion be­cause of the fun­da­men­tal role FDA plays in drug de­vel­op­ment. Now End­points is dou­bling down on reg­u­la­to­ry cov­er­age, and launch­ing a week­ly re­port fo­cus­ing on de­vel­op­ments out of White Oak, with analy­sis and in­sight in­to what it all means.

Cov­er­age will be led by our new se­nior ed­i­tor, Zachary Bren­nan. He joins End­points from POLITI­CO, where he cov­ered phar­ma. Pri­or to that he was the man­ag­ing ed­i­tor for Reg­u­la­to­ry Fo­cus, a news pub­li­ca­tion from the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.